International Clinical Trial: A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07129343) titled 'A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)' on Aug. 12.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Takeda

Condition: Von Willebrand Disease (VWD)

Intervention: Biological: VONVENDI

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: October 12, 2025

Target Sample Size: 20

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07129343

Published by HT Digital Content ...